Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Article Details
- CitationCopy to clipboard
Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.
- PubMed ID
- 28523596 [ View in PubMed]
- Abstract
PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid malignancies and hepatic impairment were enrolled into one of four cohorts: normal [bilirubin (bili) < upper limit of normal (ULN)], mild (ULN < bili
DrugBank Data that Cites this Article
- Drugs